Analyst firms · Barclays · ALVO
Barclays ALVO price target and rating history
Alvotech (ALVO) · Health Care
Barclays rates Alvotech (ALVO) Overweight with a $8 price target, as of its latest action on Sep 16, 2026. It has published 4 rating actions on ALVO since September 2023, including 2 upgrades and 0 downgrades.
- Current rating
- Overweight
- Price target
- $8
- Median target, all firms
- Too few
- Actions on ALVO
- 4
Barclays price target on ALVO
Every Barclays rating on ALVO
- Sep 16, 2026
- Dec 9, 2025
- Jan 29, 2024
- Sep 21, 2023
How other firms rate ALVO
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $8 | Sep 16, 2026 |
| BofA Securities | Buy | $7 | Aug 24, 2026 |
| Evercore ISI | Outperform | Aug 14, 2026 |
Questions about Barclays and ALVO
- What is Barclays's price target for ALVO?
- Barclays's latest stated price target for Alvotech (ALVO) is $8, from its action on Sep 16, 2026.
- What is Barclays's rating on ALVO?
- Barclays rates ALVO Overweight, a bullish rating, as of Sep 16, 2026.
- When did Barclays last change its view on ALVO?
- On Sep 16, 2026, Barclays upgrades to Overweight from Underweight, price target $8.
All Barclays ratingsALVO news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.